Ari Shamiss - Kamada Director
| KMDA Stock | ILA 2,121 23.00 1.10% |
Insider
Ari Shamiss is Director of Kamada since 2020.
| Tenure | 4 years |
| Phone | (972) 8 9406472 |
| Web | www.kamada.com |
Kamada Management Efficiency
Kamada's management efficiency ratios could be used to measure how well Kamada manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Dani Ashkenazi | Tower Semiconductor | 60 | |
| Kathleen Veit | Teva Pharmaceutical Industries | N/A | |
| Jon MD | Opko Health | 68 | |
| Kare Schultz | Teva Pharmaceutical Industries | 62 | |
| Amir Weiss | Teva Pharmaceutical Industries | 46 | |
| Haim Delmar | Elbit Systems | 49 | |
| Abbas Hussain | Teva Pharmaceutical Industries | 54 | |
| Rami Myerson | Elbit Systems | N/A | |
| Deborah Griffin | Teva Pharmaceutical Industries | N/A | |
| Eli Shani | Teva Pharmaceutical Industries | N/A | |
| Yoav Chelouche | Tower Semiconductor | 66 | |
| MBA MBA | Opko Health | 75 | |
| Noit LevyKaroubi | Tower Semiconductor | 38 | |
| James DeMarco | Opko Health | N/A | |
| Arie Gutman | Opko Health | 69 | |
| Bilha Shapira | Elbit Systems | 66 | |
| Yaacov Kagan | Elbit Systems | N/A | |
| Andrew Weil | Teva Pharmaceutical Industries | 52 | |
| Iris Avner | Tower Semiconductor | 54 | |
| Ariella Raban | Kamada | 48 | |
| Elias MD | Opko Health | 72 | |
Management Performance
| Return On Equity | -0.058 | |||
| Return On Asset | -0.0023 |
Kamada Leadership Team
Elected by the shareholders, the Kamada's board of directors comprises two types of representatives: Kamada inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kamada. The board's role is to monitor Kamada's management team and ensure that shareholders' interests are well served. Kamada's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kamada's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Pnina Strauss, Vice President - Inhalation programs & IP | ||
| Itzhak Krinsky, Director | ||
| Lilach Topilsky, Chairman of the Board | ||
| Ari Shamiss, Director | ||
| Barak Bashari, Vice President - Operations | ||
| Eran Schenker, Vice President - Medical Director | ||
| Tuvia Shoham, Independent Director | ||
| Eran Nir, Chief Officer | ||
| Hanni Neheman, VP Sales | ||
| Michal Stein, Vice President and Medical Director for Immunology | ||
| Ariella Raban, VP HR | ||
| Shani Dotan, Vice President of Human Resources | ||
| Yael Brenner, Vice President - Quality | ||
| Abraham Havron, Independent Director | ||
| Ruth Wolfson, Senior Vice President - Scientific Affairs | ||
| Shmuel Rubinstein, Director | ||
| Naveh Tov, Vice President-Clinical Development and Medical Director for Pulmonary Diseases | ||
| Jon Knight, VP Operations | ||
| Michael Berelowitz, Director | ||
| David Tsur, Co-Founder and Deputy Executive Chairman | ||
| Orit Pinchuk, Vice President - Regulatory Affairs and Quality R&D | ||
| Leon Recanati, Chairman of the Board | ||
| Jonathan Hahn, Director | ||
| Gwen Melincoff, Director | ||
| Chaime Orlev, Chief Financial Officer | ||
| Michal Ayalon, Vice President - Research & Development | ||
| Yifat Esq, Gen Legal | ||
| Amir London, Chief Executive Officer | ||
| Estery GilozRan, Independent Director | ||
| Eitan Kyiet, Vice President - Business Development |
Kamada Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kamada a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.058 | |||
| Return On Asset | -0.0023 | |||
| Profit Margin | (0.09) % | |||
| Operating Margin | (0.01) % | |||
| Current Valuation | 636.38 M | |||
| Shares Outstanding | 44.8 M | |||
| Shares Owned By Insiders | 18.50 % | |||
| Shares Owned By Institutions | 32.04 % | |||
| Price To Book | 1.13 X | |||
| Price To Sales | 5.37 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Kamada Stock
When determining whether Kamada offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kamada's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kamada Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kamada Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kamada. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Kamada Stock refer to our How to Trade Kamada Stock guide.You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.